Bernd Sporer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bernd Sporer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
H.-W. Pfister
Department of Neurology, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany
3 shared publicationsK. Seelos
Neuroradiology, Ludwig Maximilians University, Munich
2 shared publicationsR. Paul
Department of Neurology, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany
2 shared publicationsB. Popp
Department of Neurology, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany
1 shared publicationF. Asmus
Department of Neurology, University of Tübingen, Tübingen, Germany
1 shared publicationFrank D. Goebel
Ludwig-Maximilians-University Munich, Department of Neurology and Institute for Clinical Chemistry, and Medizinische Poliklinik , Munich, Germany
1 shared publication
Latest Publications
- 1 June 2005
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 163 (1-2) , 190-194
Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients
- 1 June 2005
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 163 (1-2) , 190-194
Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients
- Open Access
- 1 May 2005
- Published by S. Karger AG in European Neurology
- Vol. 53 (2) , 96-97
Posterior Fossa Tremor Induced by HIV-Associated Progressive Multifocal Leukoencephalopathy
- 1 May 2005
- Published by S. Karger AG in European Neurology
- Vol. 53 (2) , 96-97
Open AccessPosterior Fossa Tremor Induced by HIV-Associated Progressive Multifocal Leukoencephalopathy
- 23 February 2005
- Published by Springer Nature in Journal of Neurology
- Vol. 252 (3) , 356-358
HIV?induced chorea
- 23 February 2005
- Published by Springer Nature in Journal of Neurology
- Vol. 252 (3) , 356-358
HIV?induced chorea
- Open Access
- 1 February 2004
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (2) , 298-300
Vascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases
Vascular endothelial growth factor (VEGF) is a potent angiogenic and mitogenic peptide, which also induces several mediators that may play a role in HIV induced CNS damage. VEGF levels were determined in cerebrospinal fluid (CSF) and serum samples from patients with (n = 8) and without (n = 19) directly HIV associated CNS disorders and HIV negative control patients (n = 18). VEGF serum but not CSF levels were significantly increased in HIV infected patients with (381.1 (78.9) pg/ml) HIV associated CNS diseases compared with those without (120.8 (13.1) pg/ml) and HIV negative control patients (133.1(14.8) pg/ml). Serum samples from patients with untreated HIV associated encephalopathy (HIVE, n = 3) contained the highest VEGF levels (583.9 (71.5) pg/ml). In two patients VEGF serum levels were reduced during antiretroviral therapy. However, regardless of effective viral suppression, patients with HIVE still had higher levels compared with HIV infected patients without HIVE. A relevant increase of serum VEGF was not observed in patients without HIVE though high HI viral load. We conclude that HIVE is associated with increased serum VEGF levels. Further studies are warranted to elucidate the role of VEGF in HIVE.
- 1 February 2004
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (2) , 298-300
Open AccessVascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases
Vascular endothelial growth factor (VEGF) is a potent angiogenic and mitogenic peptide, which also induces several mediators that may play a role in HIV induced CNS damage. VEGF levels were determined in cerebrospinal fluid (CSF) and serum samples from patients with (n = 8) and without (n = 19) directly HIV associated CNS disorders and HIV negative control patients (n = 18). VEGF serum but not CSF levels were significantly increased in HIV infected patients with (381.1 (78.9) pg/ml) HIV associated CNS diseases compared with those without (120.8 (13.1) pg/ml) and HIV negative control patients (133.1(14.8) pg/ml). Serum samples from patients with untreated HIV associated encephalopathy (HIVE, n = 3) contained the highest VEGF levels (583.9 (71.5) pg/ml). In two patients VEGF serum levels were reduced during antiretroviral therapy. However, regardless of effective viral suppression, patients with HIVE still had higher levels compared with HIV infected patients without HIVE. A relevant increase of serum VEGF was not observed in patients without HIVE though high HI viral load. We conclude that HIVE is associated with increased serum VEGF levels. Further studies are warranted to elucidate the role of VEGF in HIVE.
- Open Access
- 1 September 1998
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 178 (3) , 854-857
Presence of Matrix Metalloproteinase‐9 Activity in the Cerebrospinal Fluid of Human Immunodeficiency Virus—Infected Patients
To determine whether matrix metalloproteinase (MMP)-9 is a potential mediator involved in the frequently detected blood-brain barrier leakage in huma
- 1 September 1998
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 178 (3) , 854-857
Open AccessPresence of Matrix Metalloproteinase‐9 Activity in the Cerebrospinal Fluid of Human Immunodeficiency Virus—Infected Patients
To determine whether matrix metalloproteinase (MMP)-9 is a potential mediator involved in the frequently detected blood-brain barrier leakage in huma